je.st
news
Tag: treatment
Treatment & Monitoring
2016-12-06 00:12:14| PortlandOnline
How the Portland Water Bureau treats and tests for lead in water, and results of lead-in-water testing.
Tags: treatment
monitoring
Albaugh launches Resonate 600 ST, a new insecticide seed treatment
2016-12-05 20:52:05| Corn & Soybean Digest
Albaugh, LLC, a leading provider of crop protection products and seed treatment technology announced they are launching a new insecticide brand for seed treatment applications. Resonate 600 ST is driven by a new innovative formulation that reduces seed treatment dust off. Chris Zita, Albaugh, LLC Director of Seed Treatments, North America, commented, read more
Tags: treatment
seed
launches
insecticide
Bayer and West Central Distribution, LLC introduce soybean seed treatment combination
2016-11-17 00:25:56| Corn & Soybean Digest
Editor’s Note: Briefing Room is where we run press releases from companies unedited, for your use. read more
Tags: west
central
distribution
treatment
Syngenta introduces two new interactive tools featuring Vibrance brand seed treatment fungicide
2016-10-25 15:49:30| Corn & Soybean Digest
Editor’s Note: Briefing Room is where we run press releases from companies unedited, for your use. As part of the ongoing commitment to provide growers and retailers with the most current crop protection products and agronomic resources, Syngenta Seedcare recently launched two new online tools. The Vibrance® seed treatment fungicide Learning Module and the Vibrance Interactive Infographic were both developed to help educate and build awareness about the impact of soilborne pathogens on root health and crop productivity in corn, soybeans and wheat. read more
Tags: tools
brand
treatment
interactive
FDA Approves Mercks KEYTRUDA (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
2016-10-25 00:04:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] next »